EZH2 and prostate adenocarcinoma: Since downregulation of cell cycle regulators upon EZH2 inhibition could contribute to the responses seen with tazemetostat in PRAD, we hypothesized that targeting cell cycle regulators may compensate for the lack of response to EZH2 inhibition in NEPC.